Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00585780 · ClinicalTrials.gov registry record · Phase 1
Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
NCT00585780 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 100 participants.
The verdict
NCT00585780, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
Study Summary
To test the preliminary efficacy of 16.0 mg of Prazosin daily versus placebo in treatment seeking alcohol dependent individuals. This proposal is a laboratory and treatment outcome study to examine the effects of Prazosin on brief exposure to stress, drug cues and neutral situations on alcohol and drug craving, mood and neurobiological reactivity in a sample of cocaine and/or alcohol dependent individuals. Prazosin will be beneficial for reduction in stress and alcohol cue induced craving and related arousal. In a sample of treatment-seeking alcohol dependent men and women, we propose to examine (a) differences in measures of alcohol craving, emotion state, hypothalamic-pituitary-adrenal (HPA) activation, physiological arousal and plasma catecholamine response to stress imagery and to alcohol cue imagery as compared to neutral imagery; (b) reduction in alcohol abstinence symptoms; and (c) improvement in alcohol treatment outcomes as measured by reductions in heavy drinking days, any drinking days, secondarily on drinks/day, anxiety, mood and sleep.
Interventions
- DRUG Placebo Tablet
- DRUG Prazosin Tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2009-09 |
| Est. Completion | 2019-05-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00585780
The ClinicalTrials.gov registry entry for NCT00585780 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo Tablet is the first listed.
NCT00585780 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00585780 about?
NCT00585780 is a clinical study titled "Prazosin to Reduce Stress-Induced Alcohol/Drug Craving and Relapse". To test the preliminary efficacy of 16.0 mg of Prazosin daily versus placebo in treatment seeking alcohol dependent individuals. This proposal is a laboratory and treatment outcome study to examine the effects of Prazosin on brief exposure to stress, drug cues and neutral situations on alcohol and d...
What is the current status of trial NCT00585780?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2009-09. Estimated completion is 2019-05-13.
What interventions are being tested in trial NCT00585780?
The interventions under investigation include: Placebo Tablet (DRUG), Prazosin Tablet (DRUG).
Who is sponsoring clinical trial NCT00585780?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.